Myeloproliferative Neoplasm Clinical Trials

21 studies are recruiting for myeloproliferative neoplasm in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Houston, Texas 7 Boston, Massachusetts 6 Duarte, California 5 Seattle, Washington 5 Atlanta, Georgia 4 Aurora, Colorado 3 Chicago, Illinois 3 Cincinnati, Ohio 3 Miami, Florida 3 Milwaukee, Wisconsin 3 Omaha, Nebraska 3 Orange, California 3 Philadelphia, Pennsylvania 3 Portland, Oregon 3 Tampa, Florida 3 Winston-Salem, North Carolina 3

Studies now recruiting

  1. Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

    This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to lower the level of metals found in the bone marrow…

    Stage
    Phase 1
    Ages
    1 and older
    Site
    M D Anderson Cancer Center, Houston, Texas
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT03630991 on ClinicalTrials.gov

  2. Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

    This phase II trial studies how well decitabine with ruxolitinib, fedratinib, or pacritinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors). Drugs used in chemotherapy, such as decitabine, work in different ways…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
    Run by
    University of Washington

    See if you can join NCT04282187 on ClinicalTrials.gov

  3. Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

    This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of cancer cells by blocki…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Dana-Farber Cancer Institute, Boston, Massachusetts
    Locations
    4 in total
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT03471260 on ClinicalTrials.gov

  4. Project: Every Child for Younger Patients With Cancer

    This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

    Stage
    Not phased
    Ages
    Up to 25
    Site
    Children's Hospital of Alabama, Birmingham, Alabama
    Locations
    279 in total
    Run by
    Children's Oncology Group

    See if you can join NCT02402244 on ClinicalTrials.gov

  5. CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

    This phase II trial investigates how well CPX-351 and ivosidenib work in treating patients with acute myeloid leukemia or high-risk myelodysplastic syndrome that has IDH1 mutation. The safety of this drug combination will also be studied. IDH1 is a type of genetic mutation (change). Chemotherapy dr…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    M D Anderson Cancer Center, Houston, Texas
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT04493164 on ClinicalTrials.gov

  6. Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant

    Cancer and treatment-related cognitive changes, such as thinking or remembering, hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk for cognitive impairment. Age is a risk factor for Alzheimer's…

    Stage
    Not phased
    Ages
    19 and older
    Site
    University of Nebraska Medical Center, Omaha, Nebraska
    Run by
    University of Nebraska

    See if you can join NCT04898790 on ClinicalTrials.gov

  7. A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

    This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cel…

    Stage
    Phase 1
    Ages
    18 to 75
    Site
    City of Hope Medical Center, Duarte, California
    Locations
    3 in total
    Run by
    City of Hope Medical Center

    See if you can join NCT07020533 on ClinicalTrials.gov

  8. Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

    This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosphamide, fludarabine and thiotepa, and TBI before …

    Stage
    Phase 2
    Ages
    0 to 65
    Site
    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
    Run by
    Fred Hutchinson Cancer Center

    See if you can join NCT06013423 on ClinicalTrials.gov

  9. Evaluation of the Pathobiology of CALR-mutated MPN Cells

    The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Atrium Health Levine Cancer, Charlotte, North Carolina
    Locations
    2 in total
    Run by
    Wake Forest University Health Sciences

    See if you can join NCT06480591 on ClinicalTrials.gov

  10. Allo HSCT Using RIC and PTCy for Hematological Diseases

    This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamid…

    Stage
    Phase 2
    Ages
    Up to 75
    Site
    Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota
    Run by
    Masonic Cancer Center, University of Minnesota

    See if you can join NCT05805605 on ClinicalTrials.gov

  11. Caris Chromoseq Data Collection

    The study will collect clinical data on patients who receive the Caris Chromoseq assay for an underlying hematologic malignancy. The assay provides risk stratification for patients with acute myeloid leukemia (AML) myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN). The hypothesi…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Caris Life Sciences, Phoenix, Arizona
    Run by
    Caris Science, Inc.

    See if you can join NCT07680868 on ClinicalTrials.gov

  12. Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

    This phase II trial studies how well vedolizumab plus post-transplant cyclophosphamide (PTCy) and short course tacrolimus work for the prevention of graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) after reduced intensity conditioning. Allo…

    Stage
    Phase 2
    Ages
    18 to 80
    Site
    City of Hope Medical Center, Duarte, California
    Run by
    City of Hope Medical Center

    See if you can join NCT06815003 on ClinicalTrials.gov

  13. A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

    This research study is studying cytokine induced memory-like natural killer (CIML NK) cells combined with IL-2 in adult patients (18 years of age or older) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) who relapse after haploidentical hemat…

    Stage
    Phase 1
    Ages
    12 and older
    Site
    Boston Children's Hospital, Boston, Massachusetts
    Locations
    2 in total
    Run by
    Dana-Farber Cancer Institute

    See if you can join NCT04024761 on ClinicalTrials.gov

  14. Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

    The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or MDS and myeloproliferative neoplasm (MP…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Dana-Farber Cancer Institute, Boston, Massachusetts
    Locations
    2 in total
    Run by
    Dana-Farber Cancer Institute

    See if you can join NCT06138587 on ClinicalTrials.gov

  15. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

    The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…

    Stage
    Not phased
    Ages
    0 to 38
    Site
    Children's Hospital Colorado, Aurora, Colorado
    Locations
    5 in total
    Run by
    Children's Hospital Medical Center, Cincinnati

    See if you can join NCT06131801 on ClinicalTrials.gov

  16. Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

    This phase II trial studies how well dexrazoxane hydrochloride works in preventing heart-related side effects of chemotherapy in participants with blood cancers, such as acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, and myeloproliferative neoplasms. Chemoprotective dru…

    Stage
    Phase 2
    Ages
    12 and older
    Site
    M D Anderson Cancer Center, Houston, Texas
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT03589729 on ClinicalTrials.gov

  17. Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

    This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in remission. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cel…

    Stage
    Phase 2
    Ages
    1 to 60
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    3 in total
    Run by
    Fred Hutchinson Cancer Center

    See if you can join NCT03970096 on ClinicalTrials.gov

  18. An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

    This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of California, Irvine, Irvine, California
    Locations
    2 in total
    Run by
    University of California, Irvine

    See if you can join NCT05123365 on ClinicalTrials.gov

  19. CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

    This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. Th…

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    City of Hope Medical Center, Duarte, California
    Locations
    3 in total
    Run by
    City of Hope Medical Center

    See if you can join NCT06059391 on ClinicalTrials.gov

  20. Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

    The purpose of this study is to learn about the impact that the services and programs provided by Blood Cancer United (formerly, The Leukemia and Lymphoma Society) have among patients with blood cancer, such as access to care, quality of life, and financial burden.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Sylvester Comprehensive Cancer Center, Miami, Florida
    Locations
    3 in total
    Run by
    University of Miami

    See if you can join NCT05745285 on ClinicalTrials.gov

  21. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Birmingham, Alabama
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.